Antibodies News and Research

RSS

Danish vs. Swedish data shows social interaction major risk factor for SARS-CoV-2 infection

A new study published on the preprint server medRxiv* in September 2020 compares the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Danish and Swedish healthcare workers, to conclude that “social interaction is one of the biggest risk factors for getting infected with SARS-CoV-2.”

30 Sep 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

29 Sep 2020

Common cold in the past may provide some protection from COVID-19

Seasonal colds are by all accounts no fun, but new research suggests the colds you've had in the past may provide some protection from COVID-19.

29 Sep 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Now, a recent study published on the preprint server medRxiv* in September 2020 shows the achievement of herd immunity for SARS-CoV-2 infection by at least some expatriate worker communities in Qatar.

29 Sep 2020

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Antibody-based immunotherapy is one of treatment options for cancer immunotherapy by modulating our immune system with therapeutic antibodies.

29 Sep 2020

Corralling the facts on herd immunity

For a term that's at least 100 years old, "herd immunity" has gained new life in 2020.

29 Sep 2020

Computer model unravels mystery behind severe inflammation in people with COVID-19

A study from the University of Pittsburgh School of Medicine and Cedars-Sinai addresses a mystery first raised in March: Why do some people with COVID-19 develop severe inflammation?

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

A recent study by French researchers has demonstrated that experimental exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) is capable of inducing mild infection in hamsters and ferrets within 7 – 10 days of exposure. However, the infection completely resolves within 14 days. The study is currently available on the bioRxiv preprint server.

28 Sep 2020

Early introduction of gluten may be an effective celiac disease prevention strategy

Introducing high doses of gluten from four months of age into infants' diets could prevent them from developing celiac disease, a study has found.

28 Sep 2020

Interdisciplinary team wins NIH grant to develop a device for early oral cancer detection

Mouth lesions are among the main early indicators of oral cancer, but determining whether a sore is actually malignant typically involves painful, costly biopsies.

28 Sep 2020

Auto-antibodies may explain why some people develop severe COVID-19

Now, a new study by an international team of health experts shows that some life-threatening cases of COVID-19 can be traced to specific weak spots in the patients' immune system.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

A multinational research group recently published a paper in the journal Lancet Respiratory Medicine which describes the first patient with a severe form of coronavirus disease (COVID-19) that was successfully treated with human recombinant soluble ACE2.

27 Sep 2020

Antibodies News and Research

Danish vs. Swedish data shows social interaction major risk factor for SARS-CoV-2 infection

Researchers identify a new method to produce miniaturized antibodies

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Common cold in the past may provide some protection from COVID-19

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Corralling the facts on herd immunity

Computer model unravels mystery behind severe inflammation in people with COVID-19

SARS-CoV-2 re-infection is real but rare: Case study

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

Early introduction of gluten may be an effective celiac disease prevention strategy

Interdisciplinary team wins NIH grant to develop a device for early oral cancer detection

Auto-antibodies may explain why some people develop severe COVID-19

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Anti-N-protein IgG may predict severity of COVID-19

Human recombinant soluble ACE2 successfully used in a patient with severe COVID-19

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo